NCT02162758View on ClinicalTrials.gov

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Barrett's Esophagus
Interventions
DRUG

Dexlansoprazole

Dexlansoprazole delayed-release capsules

DRUG

Dexlansoprazole Placebo

Dexlansoprazole placebo-matching capsules

Trial Locations (6)

27599

Chapel Hill

32216

Jacksonville

37909

Knoxville

Unknown

Jacksonville

Chapel Hill

Knoxville

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY